Cassella Aktiengesellschaft

Cassella Aktiengellschaft

Laboratoires Hoechst S/a

Cassella Aktiengessellschaft

Helmut Bohn

Karl Schonafinger

Melitta Just

Rudi Beyerle

Piero A Martorana

Rolf-Eberhard Nitz

Jorg Ostrowski

Gerhard Zoller

Joachim Brendel

Eckard Kujath

Anton Mogilev

Christian Baumgartner

Wolfgang Ruger

Thomas Raabe

Vincent Richard

Jacques Dreux

SchoKarl

Gerd Driesen

Jean-Pierre Nallet

Alain Berdeaux

Organic nitrates, processes for their preparation and their use in the

The present invention relates to hydroxymethylfurazancarboxylic acid derivatives of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents hydroxymethyl and the other represents ##STR2## where X represents NR.sup.3 R.sup.4, OH or OR.sup.7, and R.sup.3, R.sup.4 and R.sup.7 are defined as indicated in claim 1, to processes for their preparation and to their use.

Hydroxymethylfurazancarboxylic acid derivatives

The present invention relates to phenyl-1,2,5-oxadiazolecarboxamide-2-oxides of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents ##STR2## and the other represents ##STR3## and R.sup.3 and R.sup.4 are defined as indicated in claim 1, to processes for their preparation and to their use for the treatment of disorders of the cardiovascular system, including angina pectoris and erectile dysfunctions.

Phenyl-1,2,5-oxadiazolecarboxamide-2-oxides, their preparation and their

The present invention relates to phenylfuroxans of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents phenyl and the other represents ##STR2## where R.sup.3, R.sup.4 and n are defined as indicated in claim 1, processes for their preparation and their use.

Phenylfuroxans

The present invention relates to pyrimidofuroxans of the general formula I ##STR1## in which A denotes ##STR2## where in each case the nitrogen atom is bonded via the C-4 and the carbon atom via the C-3 of the furoxan ring and the R radicals are defined as indicated in Claim 1, processes for their preparation and their use for the control and prevention of disorders of the cardiovascular system, in particular for the control and prevention of angina pectoris, and for the treatment of erectile dysfunctions.

Pyrimidofuroxans, their preparation and their use

The present invention relates to pyridyl-1,2,5-oxadiazolcarboxamide-2-oxides of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents pyridyl and the other represents ##STR2## and R.sup.3 and R.sup.4 are defined as indicated in claim 1, processes for their preparation and their use.

Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxides

The present invention relates to fused 1,2,5-oxadiazole-2-oxides of the general formula I ##STR1## in which A denotes ##STR2## and X, Y, Z as well as R.sup.1, R.sup.2, R.sup.3 and n are defined as indicated in Claim 1, to processes for their preparation and to their use for the control and prevention of disorders of the cardiovascular system, in particular for the control and prevention of angina pectoris, and for the treatment of erectile dysfunctions.

Fused 1,2,5-oxadiazole-2-oxides and their use

Substituted 3-aminosydnonimines of the formula I ##STR1## and pharmacologically acceptable acid addition salts thereof, in which R.sup.1 denotes hydrogen or the radical --COR.sup.4,

Substituted 3-aminosydnonimines

The invention relates to pharmacologically active substituted 3-aminosydnone imines of the general formula I ##STR1## in which n denotes 0 or 1, and their pharmacologically acceptable salts and acid addition salts, and to a process for the preparation of the compounds according to the invention and their use.

Substituted 3-aminosydnone imines and salts thereof

Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which R.sup.1 denotes e.g. hydrogen;

Substituted 3-aminosydnone imines

The present invention relates to pharmacologically active substituted 3-dicyclohexylaminosydnone imines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which R.sup.1 denotes hydrogen or the radical --COR.sup.2 and R.sup.2 denotes (C.sub.1 to C.sub.4)-alkyl, (C.sub.1 to C.sub.4)alkoxy-(C.sub.1 to C.sub.4)alkyl, (C.sub.1 to C.sub.4) alkoxy, (C.sub.1 to C.sub.4)alkoxy-(C.sub.1 to C.sub.4 )alkoxy, (C.sub.5 to C.sub.7)cycloalkyl, phenyl, a phenyl radical which is mono-, di- or trisubstituted by 1 to 3 halogen atoms and/or 1 to 3 alkyl radicals having 1 to 4 C atoms and/or 1 to 3 alkoxy radicals having 1 to 4 C atoms, a nicotinoyl radical or an allylmercaptoacetyl radical, and to a process for the preparation of the compounds according to the invention and their use.

3-dicyclohexylaminosydnone imines, process for their preparation and

The invention relates to pharmacologically active substituted 3-aminosydnone imines of the general formula I ##STR1## in which R.sup.1 denotes (C.sub.1 -C.sub.4)-alkyl, di-(C.sub.1 -C.sub.4)-alkylamino or (C.sub.6 -C.sub.12)-aryl, which can optionally be substituted by (C.sub.1 -C.sub.4)-alkyl;

3-piperazinosydnone imines, process for their preparation and their use

Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which A denotes, for example, --CH.sub.2 --,

Substituted 3-aminosyndone imines, a process for their preparation and

The 1,2,3,4-oxatriazolium-5-olates of the formula I ##STR1## in which R.sup.1 denotes, for example, (C.sub.2 to C.sub.4)alkyl,

Substituted 1,2,3,4-oxatriazolium-5-olates, a process for their

Substituted 3-aminosydnone imines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which A denotes an alkylene chain;

Growing community of inventors

Schoneck, Germany

Helmut Bohn